Product Information
ERY 2% PADS is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $1.2348 per EA under NDC 45802096272. Its NADAC has been published 384 times since Nov 28, 2013.
FDA first approved this application on Jul 3, 1996. Its Orange Book therapeutic-equivalence code is AT.
Strength
20 mg/mL
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802096272
Classification
Generic
Dosage Form
SWAB
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
ERYTHROMYCINApproval Type
Generic (ANDA)
FDA Application
ANDA064126FDA Approved
7/3/1996
TE Code
AT
On Market Since
7/7/2008
Pharmacological Classes
Price Statistics
The NADAC for ERY 2% PADS has been published 384 times since Nov 28, 2013, and over the history we have for it it has risen 22.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2348 per EA |
|---|---|
| All-time high | $1.2380 (Aug 12, 2026) |
| All-time low | $0.8571 (May 17, 2017) |
| 52-week high | $1.2380 |
| 52-week low | $1.2121 |
| Median price | $1.0076 |
| Average price | $1.0507 |
| Largest weekly change | +28.8% (Apr 17, 2024) |
| Weeks tracked | 384 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Erythromycin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Erythromycin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Macrolide Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ERY 2% PADS?
The current National Average Drug Acquisition Cost (NADAC) for ERY 2% PADS, manufactured by Padagis Israel Pharmaceuticals Ltd, is $1.2348 per EA (NDC 45802096272), effective Sep 30, 2026.
How has the price of ERY 2% PADS changed over time?
Over the history we have for it, the NADAC for ERY 2% PADS has risen 22.7%. It has been tracked across 384 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ERY 2% PADS?
Since Nov 28, 2013, the NADAC for ERY 2% PADS has ranged from a low of $0.8571 (May 17, 2017) to a high of $1.2380 (Aug 12, 2026), with a median of $1.0076 per EA.
Are there cheaper alternatives to ERY 2% PADS?
No other NADAC-published product currently shares the active ingredient and strength of ERY 2% PADS in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ERY 2% PADS?
ERY 2% PADS (NDC 45802096272) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.